Variability in Response to Medicines in Older People: Phenotypic and Genotypic Factors

被引:74
作者
McLachlan, A. J. [1 ,2 ]
Hilmer, S. N. [3 ,4 ,5 ]
Le Couteur, D. G. [2 ]
机构
[1] Univ Sydney, Fac Pharm, St Leonards, NSW, Australia
[2] Concord Repatriat Gen Hosp, Ctr Educ & Res Ageing, Concord, NSW, Australia
[3] Univ Sydney, Dept Clin Pharmacol, St Leonards, NSW, Australia
[4] Royal N Shore Hosp, St Leonards, NSW 2065, Australia
[5] Royal N Shore Hosp, Dept Aged Care & Rehabil, St Leonards, NSW 2065, Australia
关键词
CLINICAL-PHARMACOLOGY; DRUG-INTERACTIONS; ELDERLY-PEOPLE; P-GLYCOPROTEIN; AGE; DISPOSITION; METABOLISM; FRAILTY; PHARMACOKINETICS; INFLAMMATION;
D O I
10.1038/clpt.2009.1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Understanding the causes and consequences of variability in responses to medicines is a foundation of rational therapeutics. This relies on a detailed understanding of the pharmacokinetic and pharmacodynamic characteristics of medicines and the factors that influence them in patients.(1) Ultimately the optimal dose regimen is determined by the pharmacological phenotype of the patient, which is a consequence of the person's genes and the environment in which they are expressed.(1) Older people display considerable variability in responses to medicines, and this makes dose selection a complex process.(2,3) Pharmacogenomic factors play some part in this variability, but other clinical factors also determine an older person's phenotypic response to a medicine.(1-4) In this article we conclude that with older age, genotype plays an increasingly small role in determining a person's phenotypic response to a medicine.
引用
收藏
页码:431 / 433
页数:3
相关论文
共 30 条
  • [1] Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity - Role of CYP2D6 and CYP2C19 in longevity
    Bathum, L
    Andersen-Ranberg, K
    Boldsen, J
    Brosen, K
    Jeune, B
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (05) : 427 - 430
  • [2] P-glycoprotein function in the elderly
    Brenner, SS
    Klotz, U
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (02) : 97 - 102
  • [3] Free drug metabolic clearance in elderly people
    Butler, Jennifer M.
    Begg, Evan J.
    [J]. CLINICAL PHARMACOKINETICS, 2008, 47 (05) : 297 - 321
  • [4] Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
    Evans, WE
    McLeod, HL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) : 538 - 549
  • [5] Genetics of aging
    Finch, CE
    Tanzi, RE
    [J]. SCIENCE, 1997, 278 (5337) : 407 - 411
  • [6] Frailty in older adults: Evidence for a phenotype
    Fried, LP
    Tangen, CM
    Walston, J
    Newman, AB
    Hirsch, C
    Gottdiener, J
    Seeman, T
    Tracy, R
    Kop, WJ
    Burke, G
    McBurnie, MA
    [J]. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2001, 56 (03): : M146 - M156
  • [7] Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    Gage, B. F.
    Eby, C.
    Johnson, J. A.
    Deych, E.
    Rieder, M. J.
    Ridker, P. M.
    Milligan, P. E.
    Grice, G.
    Lenzini, P.
    Rettie, A. E.
    Aquilante, C. L.
    Grosso, L.
    Marsh, S.
    Langaee, T.
    Farnett, L. E.
    Voora, D.
    Veenstra, D. L.
    Glynn, R. J.
    Barrett, A.
    McLeod, H. L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (03) : 326 - 331
  • [8] The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity
    Gorski, JC
    Vannaprasaht, S
    Hamman, MA
    Ambrosius, WT
    Bruce, MA
    Haehner-Daniels, B
    Hall, SD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (03) : 275 - 287
  • [9] Clinical pharmacology in the geriatric patient
    Hilmer, Sarah N.
    McLachlan, Andrew J.
    Le Couteur, David G.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 (03) : 217 - 230
  • [10] Plasma esterases and inflammation in ageing and frailty
    Hubbard, Ruth E.
    O'Mahony, M. Sinead
    Calver, Brian L.
    Woodhouse, Ken W.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (09) : 895 - 900